4.5 Article

Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014

Related references

Note: Only part of the references are listed.
Review Microbiology

Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

Magnus Unemo et al.

CLINICAL MICROBIOLOGY REVIEWS (2014)

Article Immunology

2012 European guideline on the diagnosis and treatment of gonorrhoea in adults

C. Bignell et al.

INTERNATIONAL JOURNAL OF STD & AIDS (2013)

Article Medicine, General & Internal

Neisseria gonorrhoeae Treatment Failure and Susceptibility to Cefixime in Toronto, Canada

Vanessa G. Allen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Letter Infectious Diseases

Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia

Marcus Y. Chen et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)

Article Infectious Diseases

Current and future treatment options for gonorrhoea

Catherine A. Ison et al.

SEXUALLY TRANSMITTED INFECTIONS (2013)

Article Infectious Diseases

Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?

Stephanie A. Chisholm et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)

Review Infectious Diseases

Azithromycin in the treatment of infection with Neisseria gonorrhoeae

Chris Bignell et al.

SEXUALLY TRANSMITTED INFECTIONS (2010)

Review Infectious Diseases

The Gonococcus fights back: is this time a knock out?

David A. Lewis

SEXUALLY TRANSMITTED INFECTIONS (2010)

Article Microbiology

Genetics of Chromosomally Mediated Intermediate Resistance to Ceftriaxone and Cefixime in Neisseria gonorrhoeae

Shuqing Zhao et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)

Article Pharmacology & Pharmacy

Meeting the public health challenge of multidrug- and extensively drug-resistantNeisseria gonorrhoeae

John W Tapsall et al.

Expert Review of Anti-Infective Therapy (2009)